Arrowhead Pharmaceuticals Inc Net Assets

Latest as of September 2025: $503.42 Million USD

Arrowhead Pharmaceuticals Inc net assets. Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has net assets worth $503.42 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.39 Billion) and total liabilities ($881.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Arrowhead Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets $503.42 Million
% of Total Assets 36.34%
Annual Growth Rate N/A
5-Year Change 23.14%
10-Year Change 429.78%
Growth Volatility 185.57

Net Assets of Arrowhead Pharmaceuticals Inc (1997–2025)

Net assets of Arrowhead Pharmaceuticals Inc from 1997 to 2025. This chart illustrates how Arrowhead Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See Arrowhead Pharmaceuticals Inc (ARWR) balance sheet quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Arrowhead Pharmaceuticals Inc (1997–2025)

The table below shows the annual net assets of Arrowhead Pharmaceuticals Inc from 1997 to 2025. For live market cap and overall valuation, see Arrowhead Pharmaceuticals Inc stock valuation.

Year Net Assets Change
2025-09-30 $503.42 Million +163.48%
2024-09-30 $191.06 Million -33.47%
2023-09-30 $287.16 Million -31.36%
2022-09-30 $418.34 Million +2.33%
2021-09-30 $408.82 Million -11.47%
2020-09-30 $461.78 Million +89.23%
2019-09-30 $244.04 Million +156.23%
2018-09-30 $95.24 Million +17.77%
2017-09-30 $80.87 Million -14.90%
2016-09-30 $95.02 Million -13.32%
2015-09-30 $109.62 Million -33.96%
2014-09-30 $165.99 Million +544.98%
2013-09-30 $25.73 Million +192.15%
2012-09-30 $8.81 Million -29.89%
2011-09-30 $12.56 Million +55.53%
2010-09-30 $8.08 Million +66.29%
2009-09-30 $4.86 Million -60.51%
2008-09-30 $12.30 Million -53.50%
2007-09-30 $26.46 Million -16.29%
2006-09-30 $31.61 Million +12.81%
2005-09-30 $28.02 Million +149.57%
2004-09-30 $11.23 Million +690.70%
2003-09-30 $1.42 Million +191.56%
2002-09-30 $-1.55 Million -18.87%
2001-09-30 $-1.30 Million -15.53%
2000-09-30 $-1.13 Million -13.36%
1999-09-30 $-996.10K +62.09%
1998-09-30 $-2.63 Million -2.00%
1997-09-30 $-2.58 Million --

Equity Component Analysis

This analysis shows how different components contribute to Arrowhead Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 161773993000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Arrowhead Pharmaceuticals Inc Net Assets Breakdown (September 2025)

Arrowhead Pharmaceuticals Inc net assets breakdown by equity component as of September 2025.

Component Amount Percentage
Common Stock $231.00K 0.05%
Other Comprehensive Income $6.44 Million 1.38%
Other Components $2.09 Billion 447.70%
Total Equity $466.05 Million 100.00%

Arrowhead Pharmaceuticals Inc Competitors by Market Cap

The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their market capitalization.

Company Market Cap
Element Solutions Inc
NYSE:ESI
 $8.35 Billion
Bid Corporation Ltd
JSE:BID
 $8.35 Billion
Restaurant Brands International Limited Partnership
TO:QSP-UN
 $8.36 Billion
Blueprint Medicines Corp
NASDAQ:BPMC
 $8.36 Billion
Redeia Corporacion S.A.
MC:RED
 $8.35 Billion
Pentair PLC
NYSE:PNR
 $8.35 Billion
Companhia Paranaense de Energia - COPEL
SA:CPLE3
 $8.34 Billion
American Airlines Group
NASDAQ:AAL
 $8.34 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Arrowhead Pharmaceuticals Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 185,444,000 to 466,052,000, a change of 280,608,000 (151.3%).
  • Net loss of 1,631,000 reduced equity.
  • New share issuances of 241,388,000 increased equity.
  • Other comprehensive income increased equity by 1,693,000.
  • Other factors increased equity by 39,158,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-1.63 Million -0.35%
Share Issuances $241.39 Million +51.79%
Other Comprehensive Income $1.69 Million +0.36%
Other Changes $39.16 Million +8.4%
Total Change $- 151.32%

Book Value vs Market Value Analysis

This analysis compares Arrowhead Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 17.19x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-09-30 $-257.62 $59.90 x
1998-09-30 $-262.77 $59.90 x
1999-09-30 $-99.61 $59.90 x
2000-09-30 $-159.91 $59.90 x
2001-09-30 $-182.34 $59.90 x
2002-09-30 $-204.49 $59.90 x
2003-09-30 $175.60 $59.90 x
2004-09-30 $7.10 $59.90 x
2005-09-30 $10.29 $59.90 x
2006-09-30 $9.60 $59.90 x
2007-09-30 $7.33 $59.90 x
2008-09-30 $3.14 $59.90 x
2009-09-30 $1.08 $59.90 x
2010-09-30 $1.41 $59.90 x
2011-09-30 $1.78 $59.90 x
2012-09-30 $0.99 $59.90 x
2013-09-30 $1.15 $59.90 x
2014-09-30 $3.55 $59.90 x
2015-09-30 $1.92 $59.90 x
2016-09-30 $1.57 $59.90 x
2017-09-30 $1.10 $59.90 x
2018-09-30 $1.15 $59.90 x
2019-09-30 $2.48 $59.90 x
2020-09-30 $4.58 $59.90 x
2021-09-30 $3.94 $59.90 x
2022-09-30 $3.78 $59.90 x
2023-09-30 $2.54 $59.90 x
2024-09-30 $1.55 $59.90 x
2025-09-30 $3.48 $59.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Arrowhead Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -0.35%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -0.20%
  • • Asset Turnover: 0.57x
  • • Equity Multiplier: 3.11x
  • Recent ROE (-0.35%) is above the historical average (-69.58%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 0.00% -1115.73% 0.71x 0.00x $-596.92K
1998 0.00% -273.32% 0.71x 0.00x $97.74K
1999 0.00% 1602.80% 0.45x 0.00x $692.61K
2000 0.00% -552.91% 0.38x 0.00x $-24.64K
2001 0.00% -1995.50% 0.20x 0.00x $-55.37K
2002 0.00% -10865.27% 0.04x 0.00x $-91.14K
2003 -6.71% 0.00% 0.00x 1.07x $-237.21K
2004 -26.76% -1287.86% 0.02x 1.26x $-3.47 Million
2005 -26.24% -1160.51% 0.02x 1.11x $-9.47 Million
2006 -61.94% -3190.35% 0.02x 1.13x $-22.06 Million
2007 -113.79% -2477.70% 0.04x 1.13x $-32.56 Million
2008 -220.19% -2078.65% 0.08x 1.40x $-28.32 Million
2009 -397.46% -513.77% 0.49x 1.59x $-19.79 Million
2010 -63.83% -931.15% 0.05x 1.37x $-6.68 Million
2011 -24.46% -1056.56% 0.02x 1.24x $-4.41 Million
2012 -191.56% -14383.61% 0.01x 1.50x $-22.23 Million
2013 -113.25% -10729.22% 0.01x 1.36x $-33.89 Million
2014 -35.20% -33502.97% 0.00x 1.10x $-75.28 Million
2015 -83.45% -24068.29% 0.00x 1.20x $-102.96 Million
2016 -85.50% -51614.63% 0.00x 1.34x $-91.28 Million
2017 -42.22% -109.46% 0.30x 1.28x $-42.52 Million
2018 -56.84% -337.32% 0.14x 1.17x $-64.03 Million
2019 27.79% 40.27% 0.48x 1.43x $43.52 Million
2020 -18.31% -96.09% 0.17x 1.13x $-130.73 Million
2021 -34.45% -101.85% 0.19x 1.74x $-181.73 Million
2022 -44.29% -72.56% 0.35x 1.74x $-216.35 Million
2023 -75.65% -85.27% 0.31x 2.82x $-232.41 Million
2024 -323.27% -16882.37% 0.00x 6.15x $-618.04 Million
2025 -0.35% -0.20% 0.57x 3.11x $-48.24 Million

Industry Comparison

This section compares Arrowhead Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $126,960,080
  • Average return on equity (ROE) among peers: -97.16%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Arrowhead Pharmaceuticals Inc (ARWR) $503.42 Million 0.00% 1.75x $8.35 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $29.61 Million
Abcellera Biologics Inc (ABCL) $830.51 Million 14.32% 0.21x $3.53 Billion
Abeona Therapeutics Inc (ABEO) $4.06 Million -282.32% 0.21x $248.75 Million
Acumen Pharmaceuticals Inc (ABOS) $225.18 Million -44.68% 0.02x $15.18 Million
Abpro Holdings, Inc. (ABP) $-75.73 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $189.45 Million -60.80% 0.14x $1.41 Billion
Arbutus Biopharma Corp (ABUS) $59.19 Million -23.76% 0.21x $834.03 Million
ABVC Biopharma Inc (ABVC) $13.30 Million -59.47% 0.58x $26.65 Million
Abivax SA American Depositary Shares (ABVX) $40.58 Million -434.26% 4.06x $7.56 Billion
ACADIA Pharmaceuticals Inc (ACAD) $17.86 Million -80.65% 0.23x $3.55 Billion

About Arrowhead Pharmaceuticals Inc

NASDAQ:ARWR USA Biotechnology
Market Cap
$8.35 Billion
Market Cap Rank
#2455 Global
#913 in USA
Share Price
$59.90
Change (1 day)
-0.98%
52-Week Range
$37.85 - $89.59
All Time High
$90.47
Categories
Companies in USA Biotechnology
About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more